RCT-2100 is under development for the treatment of cystic fibrosis (CF). The therapeutic candidate is an mRNA, encoding cystic fibrosis transmembrane conductance regulator (CFTR). It is administered ...
Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
READING HOSPITAL FOUNDATION Five Berks County professionals have been added to the Reading Hospital Foundation’s board of directors. Brian Boland, Esq., Dr. Anthony Donato, Kristi Gage-Linderman, P.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback